Alberto Roggi Selected Research

Rifampin (Rifampicin)

1/2021	High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
6/2020	Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi.
1/2020	Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alberto Roggi Research Topics

Disease

6	Tuberculosis (Tuberculoses) 01/2021 - 01/2014
2	Hearing Loss (Hearing Impairment) 01/2021 - 06/2020
2	Ototoxicity 01/2021 - 06/2020
1	Coinfection 06/2020
1	Extensively Drug-Resistant Tuberculosis 01/2014

Drug/Important Bio-Agent (IBA)

3	Rifampin (Rifampicin)FDA LinkGeneric 01/2021 - 01/2020
2	Linezolid (Zyvox)FDA Link 01/2021 - 01/2014
2	Lopinavir FDA Link 06/2020 - 01/2020
2	Rifabutin (Ansamycin)FDA Link 06/2020 - 01/2020
2	Ritonavir (Norvir)FDA Link 06/2020 - 01/2020
1	Kanamycin FDA Link 06/2020
1	lopinavir-ritonavir drug combination (Kaletra)FDA Link 01/2020
1	pretomanidIBA 01/2014
1	FluoroquinolonesIBA 01/2014
1	bedaquiline (R207910)IBA 01/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2014
1	OPC-67683IBA 01/2014

Therapy/Procedure

3	Injections 01/2021 - 01/2014